Cardiome Pharma Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies that enhance the health of patients. It offers BRINAVESS (vernakalant IV) for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and develops vernakalant (oral) for atrial fibrillation. The companys pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Market Trend Signal
Stock Analysis Software and Trading System